𝔖 Bobbio Scriptorium
✦   LIBER   ✦

The symptomatic benefit (the clinical benefit response) from the second-line chemotherapy in patients with advanced gastric adenocarcinoma

✍ Scribed by O. SENCAN; A. BUYUKCELIK; B. YALCIN; M.C. BORUBAN; H. AKBULUT; A. DEMIRKAZIK; F.C. SENLER; H. ONUR; F. ICLI

Book ID
108710489
Publisher
John Wiley and Sons
Year
2007
Tongue
English
Weight
68 KB
Volume
0
Category
Article
ISSN
0961-5423

No coin nor oath required. For personal study only.

πŸ“œ SIMILAR VOLUMES

Second-line chemotherapy with fluorourac
Second-line chemotherapy with fluorouracil, leucovorin, and irinotecan (FOLFIRI regimen) in patients with advanced small bowel adenocarcinoma after failure of first-line platinum-based chemotherapy : A multicenter AGEO study
✍ Aziz Zaanan; MΓ©lanie Gauthier; David Malka; Christophe Locher; Jean-Marc Gornet; πŸ“‚ Article πŸ“… 2010 πŸ› John Wiley and Sons 🌐 English βš– 166 KB πŸ‘ 1 views

## Abstract ## BACKGROUND: Small bowel adenocarcinoma (SBA) is a rare tumor with poor prognosis. First‐line platinum‐based chemotherapy is active in patients with advanced SBA, but data regarding second‐line chemotherapy are lacking. The aim of this study was to evaluate the efficacy and tolerabil